836
A 51-year-old man developed type 1 diabetes mellitus following 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin for chronic hepatitis C.
 A 51-year-old man: Subject; 51-year-old: Subject.Age; man: Subject.Gender; type 1 diabetes mellitus: Effect; 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin: Treatment; 24 weeks: Treatment.Time_elapsed; recombinant alpha-2b peginterferon: Treatment.Drug; ribavirin: Treatment.Drug; chronic hepatitis C.: Treatment.Disorder; recombinant alpha-2b peginterferon: Combination.Drug; ribavirin: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 A 51-year-old man: Subject; 51-year-old: Subject.Age; man: Subject.Gender; type 1 diabetes mellitus: Effect; 24 weeks of treatment with recombinant alpha-2b peginterferon plus ribavirin: Treatment; 24 weeks: Treatment.Time_elapsed; recombinant alpha-2b peginterferon: Treatment.Drug; ribavirin: Treatment.Drug; chronic hepatitis C.: Treatment.Disorder; recombinant alpha-2b peginterferon: Combination.Drug; ribavirin: Combination.Drug